BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 38169969)

  • 21. Combination of CDX2 H-score quantitative analysis with CD3 AI-guided analysis identifies patients with a good prognosis only in stage III colon cancer.
    Derangère V; Lecuelle J; Lepage C; Aoulad-Ben Salem O; Allatessem BM; Ilie A; Bouché O; Phelip JM; Baconnier M; Pezet D; Sebbagh V; Terrebonne E; Bouard G; Jooste V; Bouvier AM; Molimard C; Monnien F; Gonzalez D; Le Malicot K; Rageot D; Truntzer C; Bibeau F; Ghiringhelli F;
    Eur J Cancer; 2022 Sep; 172():221-230. PubMed ID: 35785606
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of the prognostic value of CD3, CD8, and FOXP3 mRNA expression in early-stage breast cancer patients treated with anthracycline-based adjuvant chemotherapy.
    Tsiatas M; Kalogeras KT; Manousou K; Wirtz RM; Gogas H; Veltrup E; Zagouri F; Lazaridis G; Koutras A; Christodoulou C; Pentheroudakis G; Petraki C; Bafaloukos D; Pectasides D; Kosmidis P; Samantas E; Karanikiotis C; Papakostas P; Dimopoulos MA; Fountzilas G
    Cancer Med; 2018 Oct; 7(10):5066-5082. PubMed ID: 30240146
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TGF-β1 precursor and CD8 are potential prognostic and predictive markers in operated breast cancer.
    Yu HM; Yang JL; Jiao SC; Wang JD; Li Y
    J Huazhong Univ Sci Technolog Med Sci; 2014 Feb; 34(1):51-58. PubMed ID: 24496679
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating foxp3+ regulatory T cells.
    Ladoire S; Arnould L; Apetoh L; Coudert B; Martin F; Chauffert B; Fumoleau P; Ghiringhelli F
    Clin Cancer Res; 2008 Apr; 14(8):2413-20. PubMed ID: 18413832
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer.
    Golan T; Sella T; O'Reilly EM; Katz MH; Epelbaum R; Kelsen DP; Borgida A; Maynard H; Kindler H; Friedmen E; Javle M; Gallinger S
    Br J Cancer; 2017 Mar; 116(6):697-702. PubMed ID: 28183138
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic value of circulating T-lymphocyte subsets in advanced pancreatic cancer patients treated with mFOLFIRINOX or gemcitabine.
    Tulyte S; Characiejus D; Matuzeviciene R; Janiulioniene A; Radzevicius M; Jasiunaite E; Zvirblis T; Sileikis A
    Int Immunopharmacol; 2023 Feb; 115():109722. PubMed ID: 37724957
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The prognostic effect of tumour-infiltrating lymphocytic subpopulations in bladder cancer.
    Horn T; Laus J; Seitz AK; Maurer T; Schmid SC; Wolf P; Haller B; Winkler M; Retz M; Nawroth R; Gschwend JE; Kübler HR; Slotta-Huspenina J
    World J Urol; 2016 Feb; 34(2):181-7. PubMed ID: 26055646
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multiplexed quantitative analysis of CD3, CD8, and CD20 predicts response to neoadjuvant chemotherapy in breast cancer.
    Brown JR; Wimberly H; Lannin DR; Nixon C; Rimm DL; Bossuyt V
    Clin Cancer Res; 2014 Dec; 20(23):5995-6005. PubMed ID: 25255793
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival.
    Ladoire S; Mignot G; Dabakuyo S; Arnould L; Apetoh L; Rébé C; Coudert B; Martin F; Bizollon MH; Vanoli A; Coutant C; Fumoleau P; Bonnetain F; Ghiringhelli F
    J Pathol; 2011 Jul; 224(3):389-400. PubMed ID: 21437909
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Unresectable pancreatic ductal adenocarcinoma: Role of CT quantitative imaging biomarkers for predicting outcomes of patients treated with chemotherapy.
    Cheng SH; Cheng YJ; Jin ZY; Xue HD
    Eur J Radiol; 2019 Apr; 113():188-197. PubMed ID: 30927946
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Locally advanced pancreatic cancer: association between prolonged preoperative treatment and lymph-node negativity and overall survival.
    Kadera BE; Sunjaya DB; Isacoff WH; Li L; Hines OJ; Tomlinson JS; Dawson DW; Rochefort MM; Donald GW; Clerkin BM; Reber HA; Donahue TR
    JAMA Surg; 2014 Feb; 149(2):145-53. PubMed ID: 24306217
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The impact of neoadjuvant and adjuvant immunotherapy on the survival of pancreatic cancer patients: a retrospective analysis.
    Amin S; Baine M; Meza J; Lin C
    BMC Cancer; 2020 Jun; 20(1):538. PubMed ID: 32517661
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neutrophil-lymphocyte ratio (NLR) was associated with prognosis and immunomodulatory in patients with pancreatic ductal adenocarcinoma (PDAC).
    Xiang ZJ; Hu T; Wang Y; Wang H; Xu L; Cui N
    Biosci Rep; 2020 Jun; 40(6):. PubMed ID: 32510138
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic Factors in Patients With Borderline Resectable Pancreatic Ductal Adenocarcinoma Undergoing Resection.
    Ren W; Xourafas D; Ashley SW; Clancy TE
    Am Surg; 2022 Jun; 88(6):1172-1180. PubMed ID: 33522271
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Survival outcomes of neoadjuvant therapy followed by radical resection versus upfront surgery for stage I-III pancreatic ductal adenocarcinoma: a retrospective cohort study.
    Zou Y; Gao S; Yu X; Zhou T; Xie Y; Guo X; An R; Wang X; Zhao T; Chang A; Gao C; Yu J; Hao J
    Int J Surg; 2023 Jun; 109(6):1573-1583. PubMed ID: 37132194
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic impact of immune response in resectable colorectal liver metastases treated by surgery alone or surgery with perioperative FOLFOX in the randomised EORTC study 40983.
    Tanis E; Julié C; Emile JF; Mauer M; Nordlinger B; Aust D; Roth A; Lutz MP; Gruenberger T; Wrba F; Sorbye H; Bechstein W; Schlag P; Fisseler A; Ruers T
    Eur J Cancer; 2015 Nov; 51(17):2708-17. PubMed ID: 26342674
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The local immune phenotype influences prognosis in patients with nodal-positive rectal cancer after neoadjuvant chemoradiation.
    Schollbach J; Kircher S; Wiegering A; Anger F; Rosenwald A; Germer CT; Löb S
    Int J Colorectal Dis; 2020 Feb; 35(2):365-370. PubMed ID: 31828368
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Who could complete and benefit from the adjuvant chemotherapy regarding pancreatic ductal adenocarcinoma? A multivariate-adjusted analysis at the pre-adjuvant chemotherapy timing.
    Fu N; Qin K; Li J; Jin J; Jiang Y; Deng X; Shen B
    Cancer Med; 2022 Sep; 11(18):3397-3406. PubMed ID: 35434972
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Perioperative, Spatiotemporally Coordinated Activation of T and NK Cells Prevents Recurrence of Pancreatic Cancer.
    Brooks J; Fleischmann-Mundt B; Woller N; Niemann J; Ribback S; Peters K; Demir IE; Armbrecht N; Ceyhan GO; Manns MP; Wirth TC; Kubicka S; Bernhardt G; Smyth MJ; Calvisi DF; Gürlevik E; Kühnel F
    Cancer Res; 2018 Jan; 78(2):475-488. PubMed ID: 29180478
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neoadjuvant chemotherapy is associated with improved survival in patients with left-sided pancreatic adenocarcinoma.
    Ocuin LM; Hardacre JM; Ammori JB; Rothermel LD; Mohamed A; Selfridge JE; Bajor D; Winter JM
    J Surg Oncol; 2020 Dec; 122(8):1595-1603. PubMed ID: 32844445
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.